Evidence map›Paper›PMID 35619189›Full record

Trial reportStem cell research & therapy2022

Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study.

Ying-Gang Zhu, Meng-Meng Shi, Antoine Monsel, Cheng-Xiang Dai, Xuan Dong, Hong Shen, Su-Ke Li, Jing Chang, Cui-Li Xu, Ping Li and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04276987 (A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia), which is not on this map. Cited by 126 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 7 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04276987 phase1completednot on this map

A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia

TypeinterventionalSponsorRuijin HospitalRan2020 to 2020Enrolled24ConditionsCoronavirusArmsMSCs-derived exosomes
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 7 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Review
  11. Review
  12. Nutrients · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Ying-Gang Zhu *Department of Pulmonary and Critical Care Medicine, Hua-Dong Hospital, Fudan University, 221, West Yan'an Rd., Shanghai, 200040, China. robinzyg@gmail.com.ORCID 0000-0001-7416-548X
Meng-Meng Shi *Department of Pulmonary and Critical Care Medicine, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197, Rui Jin Er Rd., Shanghai, 200025, China.
Antoine Monsel *Multidisciplinary Intensive Care Unit, Department of Anesthesiology and Critical Care, La Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne University, Paris, France.
Cheng-Xiang Dai *Cellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Xuan DongDepartment of Pulmonary and Critical Care Medicine, Wuhan Jinyintan Hospital, Wuhan, China.
Hong ShenDepartment of Pulmonary and Critical Care Medicine, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197, Rui Jin Er Rd., Shanghai, 200025, China.
Su-Ke LiCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Jing ChangCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Cui-Li XuCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Ping LiCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Jing WangCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Mei-Ping ShenCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
Cheng-Jie RenCellular Biomedicine Group Inc. (CBMG), Shanghai, China.
De-Chang ChenDepartment of Intensive Care Unit, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.
Jie-Ming QuDepartment of Pulmonary and Critical Care Medicine, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197, Rui Jin Er Rd., Shanghai, 200025, China. jmqu0906@163.com.
Shanghai Cell Therapy Research Institute · CNShanghai Jiao Tong University · CNFudan University · CNInserm · FRJinyintan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExisting clinical studies supported the potential efficacy of mesenchymal stromal cells as well as derived exosomes in the treatment of COVID-19. We aimed to explore the safety and efficiency of aerosol inhalation of the exosomes derived from human adipose-derived MSCs (haMSC-Exos) in patients with COVID-19.

methodsThe MEXCOVID trial is a phase 2a single-arm, open-labelled, interventional trial and patients were enrolled in Jinyintan Hospital, Wuhan, China. Eligible 7 patients were assigned to receive the daily dose of haMSCs-Exos (2.0 × 10

resultsSeven severe COVID-19 related pneumonia patients (4 males and 3 females) were enrolled and received nebulized haMSC-Exos. The median age was 57 year (interquartile range (IQR), 43 year to 70 year). The median time from onset of symptoms to hospital admission and administration of nebulized haMSC-Exos was 30 days (IQR, 15 days to 40 days) and 54 d (IQR, 34 d to 69 d), respectively. All COVID-19 patients tolerated the haMSC-Exos nebulization well, with no evidence of prespecified adverse events or clinical instability during the nebulization or during the immediate post-nebulization period. All patients presented a slight increase of serum lymphocyte counts (median as 1.61 × 10

conclusionsOur trial shows that a consecutive 5 days inhalation dose of clinical grade haMSC-Exos up to a total amount of 2.0 × 10

trial registrationMEXCOVID, NCT04276987.

Indexed as

COVID-19ExosomesMesenchymal Stem CellsAdipose TissueFemaleHumansMaleMiddle AgedPilot ProjectsCOVID-19ExosomesExtracellular vesiclesInhalationMesenchymal stromal cell

Identifiers

PMID35619189
PMCPMC9135389
OpenAlexW4281558588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.